Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07829809 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patients

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
1\. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA 1. Compare serum adropin levels between Obese patients with and without OSA. 2. Correlate serum adropin with OSA severity indices including the Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) and cardiovascular complications. 3. Assess the relationship between serum adropin and endothelial dysfunction markers (endothelin-1). 4. Evaluate adropin's predictive ability for endothelial impairment among OSA patients.
Trial Details
NCT Number NCT07829809
Lead Sponsor Aswan University
Conditions
(from sponsor)		 Adropin In Patients of OSA
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov